PFE
The bull case just got a speed bump
Pfizer’s been trying to sell Wall Street on a pretty classic combo meal: a fat dividend, a renewed R&D push, and enough oncology upside to make the post-COVID hangover feel temporary. HSBC just took a fork to that menu and said, not so fast.
The firm downgraded Pfizer from Buy to Hold and cut its price target to $28 from $32. Translation: the stock still looks cheap-ish, but the market may need to sit with the uncertainty for a while instead of getting an immediate glow-up.
Why HSBC got colder
The biggest issue is the pipeline. HSBC lowered its probability of success on sigvotatug vedotin to 40% after the drug’s Phase 3 stumble in non-small cell lung cancer. That matters because this is one of the programs carrying a lot of the future-growth weight, alongside atirmociclib, Pfizer’s VEGF-bispecific oncology effort, and—somewhat farther down the line—its obesity portfolio.
The annoying part for investors? The meaningful catalysts for those programs now look more like a 2027 problem than a second-half-2026 problem. In stock-market terms, that’s basically saying: “Come back later, we’re still cooking.”
Leadership changes add to the fog
HSBC also pointed to recent executive changes, including a new CFO and chief strategy officer, as another reason to pump the brakes. When the people steering the ship change, investors usually want more clarity on capital allocation, dividend discipline, and how management plans to juggle growth dreams with older-business decay.
And that old-business decay is the other elephant in the room. MFN pricing, IRA changes, and loss-of-exclusivity pressure are all expected to show up more clearly, which means Pfizer doesn’t exactly have a quiet runway.
Big picture
Pfizer still has the kind of valuation that makes value investors lean in from across the table. But cheap can stay cheap if the market keeps waiting for proof. For now, HSBC’s message is simple: Pfizer’s growth story is still alive, but it’s not exactly sprinting.